<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8"/>
<style>body{background-color:white;}</style>


</head>
<body>
<div id="ylixircpfj" style="padding-left:0px;padding-right:0px;padding-top:10px;padding-bottom:10px;overflow-x:auto;overflow-y:auto;width:auto;height:auto;">
  <style>#ylixircpfj table {
  font-family: system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji';
  -webkit-font-smoothing: antialiased;
  -moz-osx-font-smoothing: grayscale;
}

#ylixircpfj thead, #ylixircpfj tbody, #ylixircpfj tfoot, #ylixircpfj tr, #ylixircpfj td, #ylixircpfj th {
  border-style: none;
}

#ylixircpfj p {
  margin: 0;
  padding: 0;
}

#ylixircpfj .gt_table {
  display: table;
  border-collapse: collapse;
  line-height: normal;
  margin-left: auto;
  margin-right: auto;
  color: #333333;
  font-size: 12px;
  font-weight: normal;
  font-style: normal;
  background-color: #FFFFFF;
  width: auto;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #000000;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #000000;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
}

#ylixircpfj .gt_caption {
  padding-top: 4px;
  padding-bottom: 4px;
}

#ylixircpfj .gt_title {
  color: #333333;
  font-size: 14px;
  font-weight: initial;
  padding-top: 4px;
  padding-bottom: 4px;
  padding-left: 5px;
  padding-right: 5px;
  border-bottom-color: #FFFFFF;
  border-bottom-width: 0;
}

#ylixircpfj .gt_subtitle {
  color: #333333;
  font-size: 85%;
  font-weight: initial;
  padding-top: 3px;
  padding-bottom: 5px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-color: #FFFFFF;
  border-top-width: 0;
}

#ylixircpfj .gt_heading {
  background-color: #FFFFFF;
  text-align: center;
  border-bottom-color: #FFFFFF;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#ylixircpfj .gt_bottom_border {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#ylixircpfj .gt_col_headings {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #000000;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#ylixircpfj .gt_col_heading {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: bold;
  text-transform: inherit;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 6px;
  padding-left: 5px;
  padding-right: 5px;
  overflow-x: hidden;
}

#ylixircpfj .gt_column_spanner_outer {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: bold;
  text-transform: inherit;
  padding-top: 0;
  padding-bottom: 0;
  padding-left: 4px;
  padding-right: 4px;
}

#ylixircpfj .gt_column_spanner_outer:first-child {
  padding-left: 0;
}

#ylixircpfj .gt_column_spanner_outer:last-child {
  padding-right: 0;
}

#ylixircpfj .gt_column_spanner {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #000000;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 5px;
  overflow-x: hidden;
  display: inline-block;
  width: 100%;
}

#ylixircpfj .gt_spanner_row {
  border-bottom-style: hidden;
}

#ylixircpfj .gt_group_heading {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
  text-align: left;
}

#ylixircpfj .gt_empty_group_heading {
  padding: 0.5px;
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: middle;
}

#ylixircpfj .gt_from_md > :first-child {
  margin-top: 0;
}

#ylixircpfj .gt_from_md > :last-child {
  margin-bottom: 0;
}

#ylixircpfj .gt_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  margin: 10px;
  border-top-style: solid;
  border-top-width: 1px;
  border-top-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
  overflow-x: hidden;
}

#ylixircpfj .gt_stub {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-right-style: solid;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  padding-left: 5px;
  padding-right: 5px;
}

#ylixircpfj .gt_stub_row_group {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-right-style: solid;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  padding-left: 5px;
  padding-right: 5px;
  vertical-align: top;
}

#ylixircpfj .gt_row_group_first td {
  border-top-width: 2px;
}

#ylixircpfj .gt_row_group_first th {
  border-top-width: 2px;
}

#ylixircpfj .gt_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#ylixircpfj .gt_first_summary_row {
  border-top-style: solid;
  border-top-color: #D3D3D3;
}

#ylixircpfj .gt_first_summary_row.thick {
  border-top-width: 2px;
}

#ylixircpfj .gt_last_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#ylixircpfj .gt_grand_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#ylixircpfj .gt_first_grand_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-style: double;
  border-top-width: 6px;
  border-top-color: #D3D3D3;
}

#ylixircpfj .gt_last_grand_summary_row_top {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-bottom-style: double;
  border-bottom-width: 6px;
  border-bottom-color: #D3D3D3;
}

#ylixircpfj .gt_striped {
  background-color: rgba(128, 128, 128, 0.05);
}

#ylixircpfj .gt_table_body {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#ylixircpfj .gt_footnotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#ylixircpfj .gt_footnote {
  margin: 0px;
  font-size: 90%;
  padding-top: 4px;
  padding-bottom: 4px;
  padding-left: 5px;
  padding-right: 5px;
}

#ylixircpfj .gt_sourcenotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#ylixircpfj .gt_sourcenote {
  font-size: 90%;
  padding-top: 4px;
  padding-bottom: 4px;
  padding-left: 5px;
  padding-right: 5px;
}

#ylixircpfj .gt_left {
  text-align: left;
}

#ylixircpfj .gt_center {
  text-align: center;
}

#ylixircpfj .gt_right {
  text-align: right;
  font-variant-numeric: tabular-nums;
}

#ylixircpfj .gt_font_normal {
  font-weight: normal;
}

#ylixircpfj .gt_font_bold {
  font-weight: bold;
}

#ylixircpfj .gt_font_italic {
  font-style: italic;
}

#ylixircpfj .gt_super {
  font-size: 65%;
}

#ylixircpfj .gt_footnote_marks {
  font-size: 75%;
  vertical-align: 0.4em;
  position: initial;
}

#ylixircpfj .gt_asterisk {
  font-size: 100%;
  vertical-align: 0;
}

#ylixircpfj .gt_indent_1 {
  text-indent: 5px;
}

#ylixircpfj .gt_indent_2 {
  text-indent: 10px;
}

#ylixircpfj .gt_indent_3 {
  text-indent: 15px;
}

#ylixircpfj .gt_indent_4 {
  text-indent: 20px;
}

#ylixircpfj .gt_indent_5 {
  text-indent: 25px;
}

#ylixircpfj .katex-display {
  display: inline-flex !important;
  margin-bottom: 0.75em !important;
}

#ylixircpfj div.Reactable > div.rt-table > div.rt-thead > div.rt-tr.rt-tr-group-header > div.rt-th-group:after {
  height: 0px !important;
}
</style>
  <table class="gt_table" data-quarto-disable-processing="false" data-quarto-bootstrap="false">
  <thead>
    <tr class="gt_heading">
      <td colspan="5" class="gt_heading gt_title gt_font_normal" style><span class='gt_from_md'><strong>Summary of Treatment-Emergent Adverse Events</strong></span></td>
    </tr>
    <tr class="gt_heading">
      <td colspan="5" class="gt_heading gt_subtitle gt_font_normal gt_bottom_border" style><span class='gt_from_md'><em>Number (Percentage) of Subjects with TEAEs by System Organ Class</em></span></td>
    </tr>
    <tr class="gt_col_headings gt_spanner_row">
      <th class="gt_col_heading gt_columns_bottom_border gt_left" rowspan="2" colspan="1" scope="col" id="AESOC"><span class='gt_from_md'><strong>System Organ Class</strong></span></th>
      <th class="gt_center gt_columns_top_border gt_column_spanner_outer" rowspan="1" colspan="3" scope="colgroup" id="**Treatment Group**">
        <div class="gt_column_spanner"><span class='gt_from_md'><strong>Treatment Group</strong></span></div>
      </th>
      <th class="gt_col_heading gt_columns_bottom_border gt_center" rowspan="2" colspan="1" scope="col" id="Total">Total</th>
    </tr>
    <tr class="gt_col_headings">
      <th class="gt_col_heading gt_columns_bottom_border gt_center" rowspan="1" colspan="1" scope="col" id="Placebo">Placebo</th>
      <th class="gt_col_heading gt_columns_bottom_border gt_center" rowspan="1" colspan="1" scope="col" id="Xanomeline-High-Dose">Xanomeline High Dose</th>
      <th class="gt_col_heading gt_columns_bottom_border gt_center" rowspan="1" colspan="1" scope="col" id="Xanomeline-Low-Dose">Xanomeline Low Dose</th>
    </tr>
  </thead>
  <tbody class="gt_table_body">
    <tr><td headers="AESOC" class="gt_row gt_left">GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS</td>
<td headers="Placebo" class="gt_row gt_center">21 (24.4%)</td>
<td headers="Xanomeline High Dose" class="gt_row gt_center">36 (50.0%)</td>
<td headers="Xanomeline Low Dose" class="gt_row gt_center">51 (53.1%)</td>
<td headers="Total" class="gt_row gt_center">108 (35.3%)</td></tr>
    <tr><td headers="AESOC" class="gt_row gt_left">SKIN AND SUBCUTANEOUS TISSUE DISORDERS</td>
<td headers="Placebo" class="gt_row gt_center">20 (23.3%)</td>
<td headers="Xanomeline High Dose" class="gt_row gt_center">39 (54.2%)</td>
<td headers="Xanomeline Low Dose" class="gt_row gt_center">39 (40.6%)</td>
<td headers="Total" class="gt_row gt_center">98 (32.0%)</td></tr>
    <tr><td headers="AESOC" class="gt_row gt_left">NERVOUS SYSTEM DISORDERS</td>
<td headers="Placebo" class="gt_row gt_center">8 (9.3%)</td>
<td headers="Xanomeline High Dose" class="gt_row gt_center">23 (31.9%)</td>
<td headers="Xanomeline Low Dose" class="gt_row gt_center">22 (22.9%)</td>
<td headers="Total" class="gt_row gt_center">53 (17.3%)</td></tr>
    <tr><td headers="AESOC" class="gt_row gt_left">GASTROINTESTINAL DISORDERS</td>
<td headers="Placebo" class="gt_row gt_center">17 (19.8%)</td>
<td headers="Xanomeline High Dose" class="gt_row gt_center">19 (26.4%)</td>
<td headers="Xanomeline Low Dose" class="gt_row gt_center">15 (15.6%)</td>
<td headers="Total" class="gt_row gt_center">51 (16.7%)</td></tr>
    <tr><td headers="AESOC" class="gt_row gt_left">CARDIAC DISORDERS</td>
<td headers="Placebo" class="gt_row gt_center">12 (14.0%)</td>
<td headers="Xanomeline High Dose" class="gt_row gt_center">14 (19.4%)</td>
<td headers="Xanomeline Low Dose" class="gt_row gt_center">14 (14.6%)</td>
<td headers="Total" class="gt_row gt_center">40 (13.1%)</td></tr>
    <tr><td headers="AESOC" class="gt_row gt_left">INFECTIONS AND INFESTATIONS</td>
<td headers="Placebo" class="gt_row gt_center">16 (18.6%)</td>
<td headers="Xanomeline High Dose" class="gt_row gt_center">13 (18.1%)</td>
<td headers="Xanomeline Low Dose" class="gt_row gt_center">9 (9.4%)</td>
<td headers="Total" class="gt_row gt_center">38 (12.4%)</td></tr>
    <tr><td headers="AESOC" class="gt_row gt_left">PSYCHIATRIC DISORDERS</td>
<td headers="Placebo" class="gt_row gt_center">10 (11.6%)</td>
<td headers="Xanomeline High Dose" class="gt_row gt_center">7 (9.7%)</td>
<td headers="Xanomeline Low Dose" class="gt_row gt_center">11 (11.5%)</td>
<td headers="Total" class="gt_row gt_center">28 (9.2%)</td></tr>
    <tr><td headers="AESOC" class="gt_row gt_left">RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS</td>
<td headers="Placebo" class="gt_row gt_center">8 (9.3%)</td>
<td headers="Xanomeline High Dose" class="gt_row gt_center">10 (13.9%)</td>
<td headers="Xanomeline Low Dose" class="gt_row gt_center">9 (9.4%)</td>
<td headers="Total" class="gt_row gt_center">27 (8.8%)</td></tr>
    <tr><td headers="AESOC" class="gt_row gt_left">INVESTIGATIONS</td>
<td headers="Placebo" class="gt_row gt_center">10 (11.6%)</td>
<td headers="Xanomeline High Dose" class="gt_row gt_center">5 (6.9%)</td>
<td headers="Xanomeline Low Dose" class="gt_row gt_center">7 (7.3%)</td>
<td headers="Total" class="gt_row gt_center">22 (7.2%)</td></tr>
    <tr><td headers="AESOC" class="gt_row gt_left">MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS</td>
<td headers="Placebo" class="gt_row gt_center">4 (4.7%)</td>
<td headers="Xanomeline High Dose" class="gt_row gt_center">7 (9.7%)</td>
<td headers="Xanomeline Low Dose" class="gt_row gt_center">7 (7.3%)</td>
<td headers="Total" class="gt_row gt_center">18 (5.9%)</td></tr>
    <tr><td headers="AESOC" class="gt_row gt_left">INJURY, POISONING AND PROCEDURAL COMPLICATIONS</td>
<td headers="Placebo" class="gt_row gt_center">4 (4.7%)</td>
<td headers="Xanomeline High Dose" class="gt_row gt_center">5 (6.9%)</td>
<td headers="Xanomeline Low Dose" class="gt_row gt_center">5 (5.2%)</td>
<td headers="Total" class="gt_row gt_center">14 (4.6%)</td></tr>
    <tr><td headers="AESOC" class="gt_row gt_left">RENAL AND URINARY DISORDERS</td>
<td headers="Placebo" class="gt_row gt_center">4 (4.7%)</td>
<td headers="Xanomeline High Dose" class="gt_row gt_center">3 (4.2%)</td>
<td headers="Xanomeline Low Dose" class="gt_row gt_center">3 (3.1%)</td>
<td headers="Total" class="gt_row gt_center">10 (3.3%)</td></tr>
    <tr><td headers="AESOC" class="gt_row gt_left">METABOLISM AND NUTRITION DISORDERS</td>
<td headers="Placebo" class="gt_row gt_center">6 (7.0%)</td>
<td headers="Xanomeline High Dose" class="gt_row gt_center">2 (2.8%)</td>
<td headers="Xanomeline Low Dose" class="gt_row gt_center">1 (1.0%)</td>
<td headers="Total" class="gt_row gt_center">9 (2.9%)</td></tr>
    <tr><td headers="AESOC" class="gt_row gt_left">VASCULAR DISORDERS</td>
<td headers="Placebo" class="gt_row gt_center">3 (3.5%)</td>
<td headers="Xanomeline High Dose" class="gt_row gt_center">1 (1.4%)</td>
<td headers="Xanomeline Low Dose" class="gt_row gt_center">3 (3.1%)</td>
<td headers="Total" class="gt_row gt_center">7 (2.3%)</td></tr>
    <tr><td headers="AESOC" class="gt_row gt_left">EYE DISORDERS</td>
<td headers="Placebo" class="gt_row gt_center">2 (2.3%)</td>
<td headers="Xanomeline High Dose" class="gt_row gt_center">1 (1.4%)</td>
<td headers="Xanomeline Low Dose" class="gt_row gt_center">2 (2.1%)</td>
<td headers="Total" class="gt_row gt_center">5 (1.6%)</td></tr>
    <tr><td headers="AESOC" class="gt_row gt_left">SURGICAL AND MEDICAL PROCEDURES</td>
<td headers="Placebo" class="gt_row gt_center">2 (2.3%)</td>
<td headers="Xanomeline High Dose" class="gt_row gt_center">2 (2.8%)</td>
<td headers="Xanomeline Low Dose" class="gt_row gt_center">1 (1.0%)</td>
<td headers="Total" class="gt_row gt_center">5 (1.6%)</td></tr>
    <tr><td headers="AESOC" class="gt_row gt_left">EAR AND LABYRINTH DISORDERS</td>
<td headers="Placebo" class="gt_row gt_center">1 (1.2%)</td>
<td headers="Xanomeline High Dose" class="gt_row gt_center">1 (1.4%)</td>
<td headers="Xanomeline Low Dose" class="gt_row gt_center">2 (2.1%)</td>
<td headers="Total" class="gt_row gt_center">4 (1.3%)</td></tr>
    <tr><td headers="AESOC" class="gt_row gt_left">REPRODUCTIVE SYSTEM AND BREAST DISORDERS</td>
<td headers="Placebo" class="gt_row gt_center">2 (2.3%)</td>
<td headers="Xanomeline High Dose" class="gt_row gt_center">1 (1.4%)</td>
<td headers="Xanomeline Low Dose" class="gt_row gt_center">0 (0.0%)</td>
<td headers="Total" class="gt_row gt_center">3 (1.0%)</td></tr>
    <tr><td headers="AESOC" class="gt_row gt_left">CONGENITAL, FAMILIAL AND GENETIC DISORDERS</td>
<td headers="Placebo" class="gt_row gt_center">0 (0.0%)</td>
<td headers="Xanomeline High Dose" class="gt_row gt_center">2 (2.8%)</td>
<td headers="Xanomeline Low Dose" class="gt_row gt_center">1 (1.0%)</td>
<td headers="Total" class="gt_row gt_center">3 (1.0%)</td></tr>
    <tr><td headers="AESOC" class="gt_row gt_left">NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)</td>
<td headers="Placebo" class="gt_row gt_center">0 (0.0%)</td>
<td headers="Xanomeline High Dose" class="gt_row gt_center">1 (1.4%)</td>
<td headers="Xanomeline Low Dose" class="gt_row gt_center">2 (2.1%)</td>
<td headers="Total" class="gt_row gt_center">3 (1.0%)</td></tr>
    <tr><td headers="AESOC" class="gt_row gt_left">HEPATOBILIARY DISORDERS</td>
<td headers="Placebo" class="gt_row gt_center">1 (1.2%)</td>
<td headers="Xanomeline High Dose" class="gt_row gt_center">0 (0.0%)</td>
<td headers="Xanomeline Low Dose" class="gt_row gt_center">0 (0.0%)</td>
<td headers="Total" class="gt_row gt_center">1 (0.3%)</td></tr>
    <tr><td headers="AESOC" class="gt_row gt_left">SOCIAL CIRCUMSTANCES</td>
<td headers="Placebo" class="gt_row gt_center">0 (0.0%)</td>
<td headers="Xanomeline High Dose" class="gt_row gt_center">1 (1.4%)</td>
<td headers="Xanomeline Low Dose" class="gt_row gt_center">0 (0.0%)</td>
<td headers="Total" class="gt_row gt_center">1 (0.3%)</td></tr>
    <tr><td headers="AESOC" class="gt_row gt_left">IMMUNE SYSTEM DISORDERS</td>
<td headers="Placebo" class="gt_row gt_center">0 (0.0%)</td>
<td headers="Xanomeline High Dose" class="gt_row gt_center">0 (0.0%)</td>
<td headers="Xanomeline Low Dose" class="gt_row gt_center">1 (1.0%)</td>
<td headers="Total" class="gt_row gt_center">1 (0.3%)</td></tr>
  </tbody>
  <tfoot>
    <tr class="gt_sourcenotes">
      <td class="gt_sourcenote" colspan="5">TEAE = Treatment-Emergent Adverse Event (TRTEMFL = 'Y')</td>
    </tr>
  </tfoot>
</table>
</div>
</body>
</html>
